GMAB - Genmab receives $40M milestone payment in AbbVie collaboration

Genmab ([[GMAB]]) reached the first milestone in its collaboration with AbbVie with a $40M milestone payment triggered by the first patient dosed in the Phase 3 study of subcutaneous epcoritamab versus investigator's choice of chemotherapy in patients with relapsed or refractory diffuse large B-cell lymphoma.Epcoritamab is being co-developed by Genmab and AbbVie."We are very pleased that the first Phase 3 study of epcoritamab has been activated at multiple clinical sites and the first cancer patient has been dosed," CEO Jan van de Winkel commented.The milestone will be reflected in Genmab's 2021 guidance, to be published on Feb. 23, 2021.

For further details see:

Genmab receives $40M milestone payment in AbbVie collaboration